Taken together, our data show that gefitinib treatment promotes PINK1/Parkin-mediated mitophagy in both NSCLC and non-NSCLC cells without damaging mitochondrial function and morphology. The gene discussed is PINK1; the disease is non-small cell lung carcinoma.